Revenue: As of FY2025 Q2, the actual value is USD 13.03 M.EPS: As of FY2025 Q2, the actual value is USD 0.44.EBIT: As of FY2025 Q2, the actual value is USD 4.603 M.<h3>Segment Revenue</h3><ul><li>Total Income and Revenues: For the three months ended June 30, 2025, total income and revenues were $13,129,000, compared to $11,086,000 for the same period in 2024. For the six months ended June 30, 2025, total income and revenues were $29,041,000, compared to $12,576,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: For the three months ended June 30, 2025, net income was $9,191,000, compared to $15,985,000 for the same period in 2024. For the six months ended June 30, 2025, net income was $11,558,000, compared to $7,390,000 for the same period in 2024.</li><li>General and Administrative Expenses: For the three months ended June 30, 2025, general and administrative expenses were $7,802,000, compared to $11,004,000 for the same period in 2024. For the six months ended June 30, 2025, these expenses were $15,948,000, compared to $19,465,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: For the six months ended June 30, 2025, net cash provided by operating activities was $8,668,000, compared to net cash used in operating activities of $2,220,000 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used in investing activities was $26,674,000, compared to $1,350,000 for the same period in 2024.</li><li>Net Cash Used in Financing Activities: For the six months ended June 30, 2025, net cash used in financing activities was $9,925,000, compared to $6,060,000 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company expects most of its future revenue and income to be based on payments it may receive for milestones and royalties associated with its assets, as well as the periodic recognition of income under the EIR method.</li><li>Non-Core Business: The company plans to acquire Turnstone, LAVA, and HilleVax through tender offers, which are expected to close in the near future. These acquisitions are part of the company’s strategy to expand its portfolio of economic rights to future potential milestone and royalty payments.</li></ul>

XOMA Corp Pref Share 8.625 Perp 12/15/21 | 10-Q: FY2025 Q2 Revenue: USD 13.03 M